Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0BN7W
|
||||
| Former ID |
DIB002031
|
||||
| Drug Name |
Roclatan
|
||||
| Synonyms |
PG324
|
||||
| Indication | Glaucoma [ICD9: 365; ICD10:H40-H42] | Phase 3 | [1] | ||
| Company |
Aerie pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent noradrenaline transporter | Target Info | Modulator | [2] | |
| Rho associated protein kinase | Target Info | Modulator | [2] | ||
| PANTHER Pathway | Adrenaline and noradrenaline biosynthesis | ||||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | ||||
| WikiPathways | Monoamine Transport | ||||
| NRF2 pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02558400) Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension. | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.